410 Medical Secures $14 Million Series B Financing to Expand Access to Life-Saving Resuscitation Technologies

Home News 410 Medical Secures $14 Million Series B Financing to Expand Access to Life-Saving Resuscitation Technologies

DURHAM, N.C., March 17, 2025 — 410 Medical, Inc., a medical device company focused on innovative technologies for emergency and critical care, today announced the completion of a $14 million Series B financing. Existing investor Hatteras Venture Partners led the funding round with participation from Orlando Health Ventures, Ballad Ventures, OSF Healthcare, WakeMed, Rex Health Ventures, CU Healthcare Innovations Fund, and Sarnova.

“We are thrilled to add Rex Health Ventures, CU Healthcare Innovations, and Sarnova to our 410 Medical investor syndicate,” said Kyle Chenet, Chief Executive Officer at 410 Medical. “This funding accelerates our ability to expand access to LifeFlow, ensuring that critically ill patients receive timely and effective resuscitation. To date, clinicians have used LifeFlow to treat over 50,000 patients across the country in a wide variety of care settings. Patient outcomes and user feedback have been outstanding. The growing clinical adoption and positive provider feedback reinforce the need for effective resuscitation tools.”

Addressing an Urgent Need in Trauma and Emergency Care

Severe hemorrhage remains a leading cause of preventable death in the US, while sepsis affects more than one million patients annually and is the most expensive condition treated in US hospitals. Due to the limitations of traditional infusion methods, many patients with these life-threatening conditions do not receive timely resuscitation with blood or IV fluid. LifeFlow is designed to help medical providers deliver fluid and blood efficiently and effectively in any environment, improving patient outcomes when minutes matter and delays in resuscitation can lead to organ failure or death.

Hospitals and EMS teams across the US are increasingly adopting LifeFlow as part of advanced resuscitative care programs that improve outcomes for patients with hemorrhagic shock, sepsis, and other life-threatening conditions.

“We are excited about the implementation of LifeFlow at UNC Rex as we continue to advance protocols that help our emergency clinicians deliver effective resuscitation for septic shock, trauma and other time-sensitive conditions,” said Charul Haugan, MD, Medical Director of Clinical Optimization at UNC Health.

About 410 Medical, Inc.

Founded in 2013, 410 Medical is a North Carolina-based medical device company focused on advanced resuscitation technologies to improve the care of critically ill patients. Our lead product LifeFlow® received FDA clearance in 2016 and is used to enhance the administration of fluid and blood products for patients with sepsis, hemorrhagic shock, and other life-threatening conditions. 410 Medical is committed to providing innovative technologies, education, and support for emergency and critical care providers to deliver effective resuscitation when minutes matter.

For more information visit www.410medical.com

Pin

Related Posts